Cramer Rosenthal Mcglynn LLC Sells 196,907 Shares of BioLife Solutions, Inc. (NASDAQ:BLFS)

Cramer Rosenthal Mcglynn LLC cut its holdings in BioLife Solutions, Inc. (NASDAQ:BLFS - Free Report) by 17.9% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 905,752 shares of the medical equipment provider's stock after selling 196,907 shares during the quarter. Cramer Rosenthal Mcglynn LLC owned approximately 1.95% of BioLife Solutions worth $23,513,000 at the end of the most recent reporting period.

Other institutional investors have also made changes to their positions in the company. Steward Partners Investment Advisory LLC bought a new stake in shares of BioLife Solutions during the fourth quarter worth $26,000. 1620 Investment Advisors Inc. lifted its holdings in BioLife Solutions by 41.7% in the fourth quarter. 1620 Investment Advisors Inc. now owns 2,295 shares of the medical equipment provider's stock valued at $60,000 after buying an additional 675 shares during the period. Smartleaf Asset Management LLC boosted its stake in BioLife Solutions by 27.0% in the fourth quarter. Smartleaf Asset Management LLC now owns 4,469 shares of the medical equipment provider's stock valued at $117,000 after acquiring an additional 950 shares during the last quarter. KLP Kapitalforvaltning AS acquired a new stake in BioLife Solutions during the 4th quarter worth $171,000. Finally, Commonwealth of Pennsylvania Public School Empls Retrmt SYS bought a new stake in shares of BioLife Solutions during the 4th quarter valued at $201,000. 93.24% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several research analysts have recently issued reports on the company. Northland Securities raised their price target on BioLife Solutions from $28.00 to $31.00 and gave the stock an "outperform" rating in a research report on Wednesday, January 8th. HC Wainwright upped their price target on BioLife Solutions from $27.00 to $30.00 and gave the company a "buy" rating in a research note on Thursday, March 6th. Finally, StockNews.com upgraded shares of BioLife Solutions from a "sell" rating to a "hold" rating in a research report on Tuesday, April 8th. One research analyst has rated the stock with a hold rating and six have issued a buy rating to the company's stock. According to data from MarketBeat.com, BioLife Solutions presently has a consensus rating of "Moderate Buy" and an average price target of $31.17.

Insiders Place Their Bets

In other BioLife Solutions news, CMO Todd Berard sold 8,902 shares of the company's stock in a transaction that occurred on Tuesday, April 1st. The stock was sold at an average price of $22.66, for a total transaction of $201,719.32. Following the completion of the transaction, the chief marketing officer now owns 135,956 shares of the company's stock, valued at $3,080,762.96. This represents a 6.15 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Sarah Aebersold sold 2,695 shares of BioLife Solutions stock in a transaction that occurred on Monday, March 17th. The shares were sold at an average price of $25.44, for a total transaction of $68,560.80. Following the completion of the sale, the insider now owns 43,165 shares in the company, valued at $1,098,117.60. This trade represents a 5.88 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 72,127 shares of company stock worth $1,676,533. Corporate insiders own 2.20% of the company's stock.

BioLife Solutions Trading Up 10.1 %

Shares of BioLife Solutions stock traded up $2.21 during trading hours on Wednesday, hitting $24.10. The company's stock had a trading volume of 432,639 shares, compared to its average volume of 377,057. BioLife Solutions, Inc. has a 12 month low of $16.10 and a 12 month high of $29.55. The stock has a 50 day moving average of $24.41 and a 200 day moving average of $25.22. The company has a market capitalization of $1.14 billion, a PE ratio of -22.74 and a beta of 1.93. The company has a debt-to-equity ratio of 0.03, a current ratio of 2.78 and a quick ratio of 1.78.

BioLife Solutions (NASDAQ:BLFS - Get Free Report) last posted its earnings results on Monday, March 3rd. The medical equipment provider reported $0.26 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.06) by $0.32. BioLife Solutions had a negative return on equity of 6.61% and a negative net margin of 38.98%. The business had revenue of $22.71 million during the quarter, compared to analysts' expectations of $21.73 million. During the same period in the prior year, the business earned ($0.21) EPS. Analysts predict that BioLife Solutions, Inc. will post -0.3 earnings per share for the current year.

BioLife Solutions Company Profile

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.